Medicalgorithmics on a dynamic growth path in Q3 2023. Revenue up 38% y/y, driven by sales in the US: +76% y/y.
Medicalgorithmics, listed on the Warsaw Stock Exchange and a developer of globally innovative AI algorithms used in cardiology, recorded a 38% increase in revenue in the third quarter of this year, continuing its dynamic growth path. In the last quarter, the company recorded nearly PLN 7.2 million in sales revenue, including PLN 2.2 million from the US market alone, where it grew by 76% year-on-year. Since the beginning of 2025, Medicalgorithmics has already signed 19 agreements with new customers. The contracts concluded, including one with one of the largest American IDTFs, are already translating into results, and the Company anticipates further growth in revenues from their implementation in the fourth quarter and in 2026.